Payment overview · 2025
General Payments
$254.36
12 reported records · 5 companies
Healthcare provider profile · identity verified
Blas Alberto Miranda, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EL PASO, TX · NPI 1962577098
Verified facts
What the public records show
CMS Open Payments records show Blas Alberto Miranda, M.D. received $254.36 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.66 | 54.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.67 | 23.1% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.01 | 9.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.89 | 7.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.13 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.36 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $57.30 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $55.69 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $51.12 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 183 |
| Metformin Hcl | Metformin Hcl | 385 | 155 |
| Gabapentin | Gabapentin | 360 | 156 |
| Lisinopril | Lisinopril | 331 | 132 |
| Alendronate Sodium | Alendronate Sodium | 285 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 120 |
| Citalopram Hbr | Citalopram Hydrobromide | 276 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 119 |
| Carvedilol | Carvedilol | 262 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 113 |
| Simvastatin | Simvastatin | 247 | 91 |
| Losartan Potassium | Losartan Potassium | 241 | 111 |
| Glipizide | Glipizide | 233 | 93 |
| Omeprazole | Omeprazole | 214 | 90 |
| Finasteride | Finasteride | 198 | 82 |
| Alprazolam | Alprazolam | 190 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 66 |
| Tramadol Hcl | Tramadol Hcl | 156 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 139 | 63 |
| Furosemide | Furosemide | 134 | 60 |
| Spironolactone | Spironolactone | 129 | 60 |
| Montelukast Sodium | Montelukast Sodium | 125 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 124 | 48 |
| Mirtazapine | Mirtazapine | 116 | 45 |
| Trulicity | Dulaglutide | 107 | 38 |
| Famotidine | Famotidine | 104 | 52 |
| Eliquis | Apixaban | 100 | 42 |
| Memantine Hcl | Memantine Hcl | 99 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 37 |
| Pregabalin | Pregabalin | 96 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 40 |
| Donepezil Hcl | Donepezil Hcl | 93 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 39 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 86 | 36 |
| Desipramine Hcl | Desipramine Hcl | 85 | 40 |
| Prednisone | Prednisone | 84 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 28 |
| Lamotrigine | Lamotrigine | 82 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 42 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 44 |
| Januvia | Sitagliptin Phosphate | 75 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 37 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 73 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 69 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 34 |
| Allopurinol | Allopurinol | 67 | 32 |
| Methocarbamol | Methocarbamol | 67 | 43 |
| Linzess | Linaclotide | 66 | 35 |
| Sucralfate | Sucralfate | 66 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 29 |
| Cephalexin | Cephalexin | 64 | 42 |
| Meloxicam | Meloxicam | 64 | 34 |
| Benazepril Hcl | Benazepril Hcl | 63 | 18 |
| Bumetanide | Bumetanide | 59 | 24 |
| Clonidine Hcl | Clonidine Hcl | 59 | 20 |
| Ibuprofen | Ibuprofen | 57 | 41 |
| Nifedipine Er | Nifedipine | 53 | 25 |
| Fenofibrate | Fenofibrate | 51 | 24 |
| Irbesartan | Irbesartan | 51 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 30 |
| Sertraline Hcl | Sertraline Hcl | 50 | 24 |
| Meclizine Hcl | Meclizine Hcl | 49 | 25 |
| Clonazepam | Clonazepam | 48 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 17 |
| Trazodone Hcl | Trazodone Hcl | 40 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 22 |
| Xarelto | Rivaroxaban | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 16 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 16 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Atenolol | Atenolol | 31 | 13 |
| Levofloxacin | Levofloxacin | 31 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 14 |
| Folic Acid | Folic Acid | 29 | 14 |
| Glipizide Er | Glipizide | 29 | 12 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | 12 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 27 |
| Ramelteon | Ramelteon | 28 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 13 |
| Ezetimibe | Ezetimibe | 27 | 12 |
| Telmisartan | Telmisartan | 27 | 12 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Lactulose | Lactulose | 25 | 14 |
| Farxiga | Dapagliflozin Propanediol | 24 | 13 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | 18 |
| Jardiance | Empagliflozin | 22 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Cefdinir | Cefdinir | 19 | 17 |
| Fluconazole | Fluconazole | 19 | 13 |
| Torsemide | Torsemide | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Colchicine | Colchicine | 17 | 11 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Misoprostol | Misoprostol | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.36 · 12 records | ABBVIE INC. | AIRSUPRA, CAPVAXIVE, CREON, GARDASIL 9, JARDIANCE, LINZESS, MOUNJARO, The Cologuard Plus Collection Kit, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error